Menu
Not yet recruiting NCT04990336

Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis

No phase Interventional Acute Pancreatitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dachaihu decoction compound, Rhubarb single medicine, Regular therapies.
Who it may be relevant to
Registry conditions: Acute Pancreatitis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparison of Clinical Efficacy of Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis

Overview

A large number of clinical studies have shown that oral administration, external application or enema of Chinese medicine can promote the recovery of gastrointestinal function and the absorption of pancreatic inflammation. The aims of the study is to explore the application of Dachaihu Decoction Compound (DDC)and Rhubarb Single Medicine (RSM) in the Treatment of Acute Pancreatitis.

Interventions

  • Combination product Dachaihu decoction compound
    Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
  • Drug Rhubarb single medicine
    Rhubarb single medicine
  • Combination product Regular therapies
    Regular therapies, such as fluid therapy, for acute pancreatitis

Primary outcome measures

  • Significant and effective rate [Time frame: 7 days]

Eligibility criteria

Inclusion criteria

  • Age from 18 to 65 years old
  • Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset
  • Consent of the subjects, who sign the informed consent form

Exclusion criteria

  • Women who are pregnant or breastfeeding
  • Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc.
  • Patients with a history of severe heart, liver, kidney and other important organ diseases
  • Patients with mental illness and malignant tumors
  • People who have allergies, or are allergic to a certain drug ingredient

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT04990336 · ZDWY.XHNK.003

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗